My NCBI | Sign In
RSS Settings
  • Search: Skak K[au]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 22

    1.

    Endogenous IL-21 restricts CD8+ T cell expansion and is not required for tumor immunity.

    Søndergaard H, Coquet JM, Uldrich AP, McLaughlin N, Godfrey DI, Sivakumar PV, Skak K, Smyth MJ.

    J Immunol. 2009 Dec 1;183(11):7326-36. Epub 2009 Nov 13.PMID: 19915059 [PubMed - in process]Related articles

    2.

    IL-21: roles in immunopathology and cancer therapy.

    Søndergaard H, Skak K.

    Tissue Antigens. 2009 Oct 21. [Epub ahead of print]PMID: 19845910 [PubMed - as supplied by publisher]Related articles

    3.

    In vivo antitumor efficacy of interleukin-21 in combination with chemotherapeutics.

    Skak K, Søndergaard H, Frederiksen KS, Ehrnrooth E.

    Cytokine. 2009 Dec;48(3):231-8. Epub 2009 Aug 25.PMID: 19709902 [PubMed - in process]Related articles

    4.

    Clinical and biological efficacy of recombinant human interleukin-21 in patients with stage IV malignant melanoma without prior treatment: a phase IIa trial.

    Davis ID, Brady B, Kefford RF, Millward M, Cebon J, Skrumsager BK, Mouritzen U, Hansen LT, Skak K, Lundsgaard D, Frederiksen KS, Kristjansen PE, McArthur G.

    Clin Cancer Res. 2009 Mar 15;15(6):2123-9. Epub 2009 Mar 10.PMID: 19276257 [PubMed - indexed for MEDLINE]Related articles

    5.

    The combination of IL-21 and IFN-alpha boosts STAT3 activation, cytotoxicity and experimental tumor therapy.

    Eriksen KW, Søndergaard H, Woetmann A, Krejsgaard T, Skak K, Geisler C, Wasik MA, Odum N.

    Mol Immunol. 2009 Feb;46(5):812-20. Epub 2008 Oct 22.PMID: 18947877 [PubMed - indexed for MEDLINE]Related articles

    6.

    Immune activation in advanced cancer patients treated with recombinant IL-21: multianalyte profiling of serum proteins.

    Dodds MG, Frederiksen KS, Skak K, Hansen LT, Lundsgaard D, Thompson JA, Hughes SD.

    Cancer Immunol Immunother. 2009 Jun;58(6):843-54. Epub 2008 Oct 17.PMID: 18925392 [PubMed - indexed for MEDLINE]Related articles

    7.

    IL-21 induces in vivo immune activation of NK cells and CD8(+) T cells in patients with metastatic melanoma and renal cell carcinoma.

    Frederiksen KS, Lundsgaard D, Freeman JA, Hughes SD, Holm TL, Skrumsager BK, Petri A, Hansen LT, McArthur GA, Davis ID, Skak K.

    Cancer Immunol Immunother. 2008 Oct;57(10):1439-49. Epub 2008 Feb 20.PMID: 18286285 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    Interleukin 21: combination strategies for cancer therapy.

    Skak K, Kragh M, Hausman D, Smyth MJ, Sivakumar PV.

    Nat Rev Drug Discov. 2008 Mar;7(3):231-40. Review. Erratum in: Nat Rev Drug Discov. 2008 Mar;7(3):272. PMID: 18259184 [PubMed - indexed for MEDLINE]Related articles

    9.

    Interleukin-21 signaling: functions in cancer and autoimmunity.

    Davis ID, Skak K, Smyth MJ, Kristjansen PE, Miller DM, Sivakumar PV.

    Clin Cancer Res. 2007 Dec 1;13(23):6926-32. Review.PMID: 18056166 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    Interleukin-21 activates human natural killer cells and modulates their surface receptor expression.

    Skak K, Frederiksen KS, Lundsgaard D.

    Immunology. 2008 Apr;123(4):575-83. Epub 2007 Nov 14.PMID: 18005035 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    IL-21 induces apoptosis of antigen-specific CD8+ T lymphocytes.

    Barker BR, Parvani JG, Meyer D, Hey AS, Skak K, Letvin NL.

    J Immunol. 2007 Sep 15;179(6):3596-603.PMID: 17785794 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    An open-label, two-arm, phase I trial of recombinant human interleukin-21 in patients with metastatic melanoma.

    Davis ID, Skrumsager BK, Cebon J, Nicholaou T, Barlow JW, Moller NP, Skak K, Lundsgaard D, Frederiksen KS, Thygesen P, McArthur GA.

    Clin Cancer Res. 2007 Jun 15;13(12):3630-6.PMID: 17575227 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    Minimal impact of a de novo-expressed beta-cell autoantigen on spontaneous diabetes development in NOD mice.

    Martinic MM, Juedes AE, Bresson D, Homann D, Skak K, Huber C, Ling E, Ejrnaes M, Wolfe T, Togher L, Christen U, von Herrath MG.

    Diabetes. 2007 Apr;56(4):1059-68.PMID: 17395746 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    Interleukin 21 therapy increases the density of tumor infiltrating CD8+ T cells and inhibits the growth of syngeneic tumors.

    Søndergaard H, Frederiksen KS, Thygesen P, Galsgaard ED, Skak K, Kristjansen PE, Odum N, Kragh M.

    Cancer Immunol Immunother. 2007 Sep;56(9):1417-28. Epub 2007 Feb 7.PMID: 17285290 [PubMed - indexed for MEDLINE]Related articles

    15.

    Preservation of beta-cell function during immune-mediated, B7-1-dependent alpha-cell destruction.

    Skak K, Haase C, Michelsen BK.

    Eur J Immunol. 2005 Sep;35(9):2583-90.PMID: 16078275 [PubMed - indexed for MEDLINE]Related articles

    16.

    Local activation of dendritic cells leads to insulitis and development of insulin-dependent diabetes in transgenic mice expressing CD154 on the pancreatic beta-cells.

    Haase C, Skak K, Michelsen BK, Markholst H.

    Diabetes. 2004 Oct;53(10):2588-95.PMID: 15448088 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    Improved beta-cell survival and reduced insulitis in a type 1 diabetic rat model after treatment with a beta-cell-selective K(ATP) channel opener.

    Skak K, Gotfredsen CF, Lundsgaard D, Hansen JB, Sturis J, Markholst H.

    Diabetes. 2004 Apr;53(4):1089-95.PMID: 15047626 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    TNF-alpha impairs peripheral tolerance towards beta-cells, and local costimulation by B7.1 enhances the effector function of diabetogenic T cells.

    Skak K, Guerder S, Picarella DE, Brenden N, Flavell RA, Michelsen BK.

    Eur J Immunol. 2003 May;33(5):1341-50.PMID: 12731060 [PubMed - indexed for MEDLINE]Related articles

    19.

    Histone deacetylase inhibitors: a new class of immunosuppressors targeting a novel signal pathway essential for CD154 expression.

    Skov S, Rieneck K, Bovin LF, Skak K, Tomra S, Michelsen BK, Ødum N.

    Blood. 2003 Feb 15;101(4):1430-8. Epub 2002 Oct 17.PMID: 12393479 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    PDX-1 mediates glucose responsiveness of GAD(67), but not GAD(65), gene transcription in islets of Langerhans.

    Pedersen AA, Petersen HV, Videbaek N, Skak K, Michelsen BK.

    Biochem Biophys Res Commun. 2002 Jul 12;295(2):243-8.PMID: 12150938 [PubMed - indexed for MEDLINE]Related articles

    21.

    Characterization of the rat GAD67 gene promoter reveals elements important for basal transcription and glucose responsiveness.

    Pedersen AA, Videbaek N, Skak K, Petersen HV, Michelsen BK.

    DNA Seq. 2001;11(6):485-99.PMID: 11696975 [PubMed - indexed for MEDLINE]Related articles

    22.

    The TATA-less rat GAD65 promoter can be activated by Sp1 through non-consensus elements.

    Skak K, Michelsen BK.

    Gene. 1999 Aug 20;236(2):231-41.PMID: 10452943 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    2 free full-text articles in PubMed Central

    Find related data

    Search details

    » See more...

    Recent activity